Nigerian Institute of Medical Research

What Nigerian Institute of Medical Research does

The Nigerian Institute of Medical Research (NIMR) is Nigeria's foremost government medical research institute, established in 1920 and operating under the Federal Ministry of Health. Headquartered in Yaba, Lagos, with 501-1000 employees, NIMR conducts basic, applied, and operational research to inform national health policy, develop local vaccines and diagnostics, and address diseases of high burden in Nigeria. The institute is organized into specialized departments (Microbiology, Clinical Sciences, Molecular Biology & Biotechnology, Public Health & Epidemiology, Biochemistry & Nutrition) and maintains outstation offices in Abuja, Maiduguri, New Bussa, and Asaba. It serves the Federal Government of Nigeria as its primary institutional stakeholder, alongside international organizations (WHO, MPP, CDC, Afrigen), Nigerian universities and medical schools, and the general public through specialist clinics and diagnostic services.

NIMR's core technology and infrastructure assets include a Central Research Laboratory, a BIOBANK housing over 400,000 biological samples, clinical trials infrastructure, and a Vector Control & Entomology Laboratory. The institute is advancing an mRNA vaccine development program validated by WHO and the Medicines Patent Pool, produces locally manufactured diagnostic kits, and operates a 100 KVA solar power system (commissioned at N300 million) to support research continuity. Key research programs include SARMAAN (azithromycin mass administration reaching over 4 million infants), onchocerciasis elimination (37 million people taken off river blindness, treatment interrupted in 10 states), HIV/AIDS counseling (4 years of zero mother-to-child transmission), malaria research, antimicrobial resistance surveillance, and HPV/cervical cancer studies. The institute also maintains a Central Research Laboratory, E-Library with electronic document portal, and access to peer-reviewed biomedical databases (AJOL, DOAJ, BioOne, BMJ, PLOS, LILACS).

NIMR operates as a government parastatal with no commercial revenue model; funding derives from federal appropriations, international grants and partnerships, and the NIMR Foundation (a fundraising arm that raised N500 million in late 2025). Pricing for clinical and diagnostic services is not publicly disclosed. The institute's go-to-market approach is institutional: it delivers research, evidence, and technical expertise to federal and state health agencies, conducts clinical trials and vaccine development through international collaborations (notably with Afrigen, Chinese institutions, and the EU/Expertise France Qualimedsmafplus project), and provides specialist outpatient services and diagnostic testing to referred patients. Recent strategic positioning includes designation as a regional hub for mRNA vaccine technology adoption in Africa and pursuit of a regional pharmaceutical manufacturing coordinating role.

Name

Nigerian Institute of Medical Research

Legal name

Nigerian Institute of Medical Research

Website

https://nimr.gov.ng

Company type

Private

Founded year

1920

Operating status

Operating

Headcount range

501–1,000 employees

Short description

NIMR is Nigeria's foremost government medical research institute under the Federal Ministry of Health, conducting basic, applied, and operational research to address national health challenges, develop local vaccines and diagnostics, and provide specialist clinical services.

Ownership category

akta.pro rank

Headquarters

HQ city

Lagos

HQ country

Nigeria

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Distribution channels4 records

Marketing channels8 records

Core offering

The Nigerian Institute of Medical Research (NIMR) is Nigeria's foremost government medical research institute, conducting basic, applied, and operational research to promote national health. It provides clinical diagnostic services across multiple specialties, operates research laboratories and a BIOBANK with over 400,000 biological samples, conducts clinical trials, develops vaccines and diagnostics (including mRNA technology), and runs disease-specific research programs on malaria, HIV, HPV, antimicrobial resistance, and onchocerciasis. NIMR also offers biomedical library services, researcher training, and specialist outpatient clinics.

Product overview

The Nigerian Institute of Medical Research (NIMR) is a premier medical research institution that operates as a single integrated research organization rather than a product-based company. NIMR provides a comprehensive portfolio of research services and facilities including clinical diagnostic services across multiple specialties (cardiology, hepatology, maternal health, hematology), a Central Research Laboratory, a BIOBANK with over 400,000 biological samples, clinical trials services, and specialized research programs. These services are complemented by HIV/AIDS counseling and testing, malaria research, antimicrobial resistance surveillance, HPV/cervical cancer research, and onchocerciasis control programs. NIMR also operates an E-Library with electronic document access and biomedical journal subscriptions. The institute is advancing mRNA vaccine development capabilities and conducts the monthly SARMAAN program for infant mortality reduction. Key infrastructure includes a 100KVA solar power system and multiple specialized laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• BIOBANK: A biological sample repository housing over 400,000 samples for disease research tailored to Nigeria's health challenges.
• SARMAAN Project
• NIMR Foundation

Products and services

• Central Research Laboratory State-of-the-art laboratory facilities supporting basic, applied, and operational research for national health promotion and development in Nigeria.
• BIOBANK A biobank facility housing over 400,000 biological samples designed to transform disease research and strengthen Nigeria's response to local health challenges.
• Clinical Diagnostic Services Provides diagnostic testing services across multiple specialty areas including hypertension/nephrology/cardiology, hepatitis and gastroenterology, child health, maternal and reproductive health, and hematology.
• Clinical Trials Evidence-based clinical trials aimed at boosting capacity for local vaccine and drug manufacturing in Nigeria, with a national clinical trial network linking universities, hospitals, and other institutions.
• SARMAAN Program A pioneering intervention program administering azithromycin to infants to reduce infant mortality, with over 4 million children benefiting from the initiative.
• HIV/AIDS Counseling and Testing Comprehensive HIV counseling, testing, and ongoing care support services with zero mother-to-child HIV transmission achieved for 4 years.
• mRNA Vaccine Development Program Advanced mRNA vaccine development program with WHO and MPP validation, positioning NIMR as a regional hub for mRNA vaccine development in Africa.
• Vector Control and Entomology Laboratory Research and control services for disease vectors including detection of non-native malaria vector Anopheles stephensi in Nigeria.
• Malaria Research Services Comprehensive malaria research including treatment policy studies, rapid test reliability validation, and wastewater surveillance implementation.
• Antimicrobial Resistance Research Studies and surveillance on rising antimicrobial resistance threats in Nigeria, including third-generation antibiotic resistance monitoring.
• HPV and Cervical Cancer Research Nationwide studies on human papillomavirus prevalence among Nigerian women, warning of rising cervical cancer threats linked to persistent HPV infections.
• Onchocerciasis (River Blindness) Research Research program focused on river blindness elimination, with treatment declared interrupted in 10 states and 37 million people taken off the disease.
• E-Library and Electronic Document Portal Digital access to annual reports, research publications, newsletters, training manuals, conference proceedings, and institutional policies including a compendium of research publications from 1970-2016.
• Biomedical Databases and E-Journals Access Free access to peer-reviewed journals and databases including African Journals Online (AJOL), Directory of Open Access Journals (DOAJ), BioOne, BMJ Central, PLOS, and LILACS.

Quantifiable outcome

• 4+ million children treated through SARMAAN azithromycin mass administration program, contributing to infant mortality reduction
• +4 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Federal University Lokoja (FUL)coreStrategic or Co-development Partner · 11 June 2026NIMR and Federal University Lokoja signed a Memorandum of Understanding aimed at strengthening collaboration in biomedical research, capacity building, and academic exchange. The MoU represents NIMR's strategy to extend research collaboration to Nigerian universities.
• Chinese Academy of SciencescoreStrategic or Co-development Partner · 2 April 2026A high-level Chinese scientific delegation led by virologist Prof. George Gao of the Chinese Academy of Sciences visited NIMR to explore collaboration in infectious disease research, vaccine development, and capacity building. Experts from China CDC, Peking University, and Shanghai Junshi Biosciences participated, with Peking University presenting next-generation Mpox vaccine development using a novel chimeric immunogen approach targeting affordability for Africa.
• China CDCcoreStrategic or Co-development Partner · 2 April 2026China CDC joined the Chinese delegation visit to NIMR to explore collaboration in infectious disease research and vaccine development, representing China's national disease control authority in the partnership discussions.
• Peking UniversitycoreStrategic or Co-development Partner · 2 April 2026Prof. Han Wang of Peking University presented next-generation Mpox vaccine development using a novel chimeric immunogen approach. The presentation targeted affordability for Africa, where current vaccines cost over $60 per dose. Peking University is a key academic research partner in the collaboration.
• Shanghai Junshi BiosciencesminorStrategic or Co-development Partner · 2 April 2026Shanghai Junshi Biosciences participated in the Chinese delegation visit to NIMR, exploring potential collaboration in vaccine development and capacity building.
• Expertise France (EU-supported Qualimedsmafplus/Kalima Project)coreStrategic or Co-development Partner · 1 December 2025Expertise France, implementing a European Union-supported pharmaceutical manufacturing initiative, expressed strong interest in designating NIMR as a regional coordinating hub for Nigeria and Africa under the Qualimedsmafplus (Kalima) Project. This partnership aims to advance local drug production capacity.
• Association of Provosts of Colleges of Medicine (APCOM)minorStrategic or Co-development Partner · 1 December 2025APCOM called for deeper collaboration between Nigeria's medical schools and NIMR to strengthen research output, training, and health innovation, as part of federal government moves to rehabilitate medical schools.
• United States ResearchersminorStrategic or Co-development Partner · 30 October 2025NIMR collaborated with researchers from the United States on a groundbreaking study probing the side effects of antiretroviral therapy, expanding its international research collaborations in HIV care.
• Afrigen (South Africa)coreStrategic or Co-development Partner · 7 October 2025NIMR scientists returned from South Africa where they received advanced training at Afrigen, pushing the mRNA vaccine project to a new level as part of Africa's effort to build local vaccine manufacturing capacity.
• Excellence Community Education Welfare Scheme (ECEWS)coreStrategic or Co-development Partner · 26 September 2025ECEWS, through the US Government-funded ACE-5 project, donated medical and office equipment to NIMR to boost HIV response in Lagos. ECEWS also commissioned a 100 KVA solar power facility at NIMR as part of efforts to strengthen healthcare research infrastructure.
• World Health Organization (WHO) and Medicines Patent Pool (MPP)coreStrategic or Co-development Partner · 8 September 2025WHO and MPP validated NIMR's preparedness for mRNA vaccine technology adoption, positioning NIMR as a regional hub for mRNA vaccine development in Africa. This validation followed the return of NIMR scientists from Afrigen in South Africa where they received advanced mRNA vaccine training.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• U.S. Centers for Disease Control and Prevention (CDC): Global benchmark for national public health reference laboratories and disease surveillance infrastructure, referenced in NIMR's international partnerships. Illustrative of the scale and capability ceiling for NIMR's reference laboratory mandate.
• Indian Council of Medical Research (ICMR): India's apex medical research body, mentioned in NIMR context as a peer country that has surpassed Nigeria in research output. Provides a scaled-up reference point for what an emerging-economy national research institute can become.

Direct peers

• South African Medical Research Council (SAMRC): South Africa's statutory medical research council funding and conducting health research, with strong ties to Afrigen and the mRNA vaccine hub ecosystem. Comparable mandate in disease burden research and clinical trials for sub-Saharan Africa.
• MRC Unit The Gambia at LSHTM: A long-established West African clinical and epidemiology research unit operating vaccines, diagnostics, and child health trials. Comparable in clinical trials infrastructure and tropical disease research focus.
• Kenya Medical Research Institute (KEMRI): Kenya's national medical research institute operating under the Ministry of Health, conducting biomedical research, clinical trials, and public health surveillance. Most direct functional analog to NIMR in East Africa, with comparable portfolio of diagnostics, vaccine research, and disease surveillance.
• Institut Pasteur de Dakar: Senegal-based biomedical research institute with active vaccine manufacturing capacity (including yellow fever and measles). Closest comparator to NIMR's emerging mRNA ambitions, and a potential competitor for regional mRNA vaccine hub designation.
• Armauer Hansen Research Institute (AHRI) Ethiopia: Ethiopia's national biomedical research institute focused on tuberculosis, HIV, and neglected tropical diseases. Comparable as an African government-affiliated research institute conducting clinical and laboratory research.
• Noguchi Memorial Institute for Medical Research (University of Ghana): Ghana's leading biomedical research institute with virology, immunology, and clinical trial capabilities, including West African regional surveillance functions. Functionally similar to NIMR in scope and West African disease focus.

Emerging players

• Afrigen Biologics and Vaccines: South African mRNA vaccine technology transfer hub where NIMR scientists received training. Direct strategic partner and the most relevant comparator for NIMR's emerging mRNA manufacturing capability, though operating at a more advanced commercial scale.

Regional players

• African Population and Health Research Center (APHRC): Pan-African health research organization generating African-specific population health evidence. Comparable in mission to generate African-relevant health data, though more focused on policy research than laboratory science.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/nimrnigeria
• YouTubeyoutube.com/@nimrnigeria?si=cqnufV0JpAAOqFSy
• Facebookfacebook.com/nimrnigeria
• LinkedInlinkedin.com/company/nimrnigeria
• Instagraminstagram.com/nimrnigeria?utm_source=qr&igsh=N29oODVidHpvNTBn

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nigerian Institute of Medical Research